更新
10月6日 - ** 药物开发商Skye Bioscience SKYE.O股价下跌61.1%，跌至1.85美元的近 五个月低点
** 接受 尼马单抗（nimacimab (link)）治疗的患者 体重减轻了1.26%（按安慰剂比例调整），低于公司预期的5%至8%。
** SKYE说，研究结果可能表明，作为一种单一疗法，需要加大药物剂量
** 底线是，从今天报告的数据来看，我们还不能确信，如果更高的剂量/更好的接触能够带来足够的减重效果，从而具有竞争力，这仍将是一个'给我看'的故事"--Cantor Fitzgerald
** 包括盘中走势在内，该股今年累计下跌 33.2
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.